← All trials
NCT02200614
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2014
- Primary completion
- Apr 16, 2018
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- BayerLead sponsor
- BayerStudy director
- Orion CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.